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An international group of researchers investigating the molecular, cellular, immunological, and clinical
aspects of the autoimmune lymphoproliferative syndrome (ALPS) met in Bethesda, Maryland on September
21-22, 2009 to discuss advancesmade over the past 15 years. Their discussions yielded ten broadmessages
applicable to genetic and immunological investigations of human disease.The autoimmune lymphoproliferative syn-
drome (ALPS) is one of the first and best
understood genetic diseases involving
defective apoptosis and autoimmunity
(Rieux-Laucat et al., 1995; Fisher et al.,
1995). On September 21–22, 2009, an
international group of investigators met at
the National Institutes of Health (NIH) to
discuss insights gained from extensive
studies of several hundred ALPS families
over the past 15 years. Jennifer Puck
(University of California, San Francisco,
USA) reviewed the disease definition,
which comprises chronic lymphadenop-
athy and/or splenomegaly, defective
lymphocyte apoptosis, and a striking
elevation of CD4CD8 (double negative),
B220+ T cell receptor (TCR) ab+ T cells
(DNT cells). Typically, adults have <1%
DNT cells, whereas ALPS patients exhibit
expansions from 2% to 40%, which corre-
late with disease severity. Although not
completely resolved, DNT cells apparently
arise from CD8+ T cells by an unknown
peripheral process rather than during
thymic development. ALPS patients have
autoantibody-mediated hematological
deficiencies or ‘‘cytopenias’’ such as
Coombs positive autoimmune hemolytic
anemia, neutropenia, and thrombocyto-
penia. Deficiencies in Fas (also known as
CD95, APO-1) apoptosis and related path-
ways constitute the genetic basis of the
disease. Over the two days of talks and
discussions, ten clear ‘‘take-home’’ les-
sons that can be applied to genetic and
immunological diseases emerged.
Lesson 1
Michael Lenardo (NIH, USA) recounted
initial experiments demonstrating an apo-ptosis defect in ALPS patients and the
dominant-interfering effect of ALPS al-
leles in transfection assays. Most ALPS
patients harbor heterozygous mutations
in the Fas gene that encode defective,
dominant-interfering Fas proteins (Type
Ia) (Figure 1). The Fas receptor, similar
to others in the TNF receptor (TNFR)
superfamily, operates as a homotrimeric
complex, which can be functionally
‘‘poisoned’’ by even a single defective
subunit. The N-terminal preligand as-
sembly domain (PLAD) is preserved so
that the defective and normal receptor
chains can associate (Figure 1). In non-
consanguineous humans, this dominant
interference mechanism explains how
heterozygous defects cause ALPS and
may explain other diseases involving
apoptosis pathways and TNFR super-
family receptors. Indeed, dominant
mutations cause defective assembly of
the TNF-R family member TACI subunits
in common variable immunodeficiency
(Garibyan et al., 2007). Lesson #1: in
outbred human populations, dominant-
interfering rather than loss-of-function
genemutations may predominate in path-
ways that require protein complexes.
Lesson 2
Frederic Rieux-Laucat (Hoˆpital Necker,
INSERM, France) described his discovery
that ALPS patients can exhibit somatic
Fas mutations selectively in the DNT cells
and other minor lymphocyte subpopula-
tions (ALPS Type 1 m) (Holzelova et al.,
2004). These patients are a phenocopy of
ALPS patients with germline mutations,
indicating that DNT cells may be the main
pathogenetic catalyst for the disease.Immunity 3Type 1 m accounts for up to 30% of the
patients without germline mutations.
Lesson #2: in immune diseases involving
the emergence of unexpected cell popula-
tions, somatic pathogenic gene mutations
limited to a subset of cells that confer a
selectivesurvivaladvantagemaybe found.
Lesson 3
Tom Fleisher (NIH, USA) discussed how
ALPS involves more than a single Mende-
lian trait. Gene mutations leading to ALPS
have been designated subtypes I to IV
(Figure 1). Themajority of mutations affect
the Fas signaling apparatus, called the
‘‘death-inducing signaling complex’’
(DISC). Type Ia represents mutations in
the Fas (TNFRSF6) gene on chromosome
10q24. Most Fas mutations (more than
70%) in ALPS Type Ia patients alter the in-
tracytoplasmic death domain and cause
the prototypical clinical phenotype. Type
Ib involves mutations in the Fas ligand
(TNFSF6, M5) gene on chromosome 1
(map position 1 H2.1j1 85.0 cM). These
also generate dominant-interfering pro-
teins because the ligand also operates
as a trimeric complex. Type II ALPS is
due to dominant-interfering mutations in
caspase-10 (CASP10; chromosome 2,
map position 626.70). A disease related
to ALPS, called caspase-8 deficiency
state (CEDS), is caused by loss-of-func-
tion mutations in caspase-8 (CASP8;
chromosome 2, map position 626.70), a
close paralog occupying the same ge-
nomic locus as caspase-10. CEDS shares
the lymphoproliferation and apoptosis
defect observed with ALPS but exhibits
immunodeficiency rather than autoimmu-
nity (Chun et al., 2002). Caspase-8 has2, March 26, 2010 ª2010 Elsevier Inc. 291
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Figure 1. Molecular Basis for ALPS Genetic Mutations and Clinical
Classification
Molecules involved in canonical Fas signaling are illustrated on top and the
normal signaling pathway on the left. Membrane-bound Fas ligand binds the
preassociated trimeric Fas and triggers formation of the death-inducing
signaling complex (DISC) by recruiting adaptor FADD (Fas-associated death
domain) protein, caspase-8 (Casp8) and/or caspase-10 (Casp10). On the right,
the identified genemutations in ALPS and ALPS-like patients are linked to their
clinical classifications. The percentage incidence for each type is shown in
parenthesis. Mutations for ALPS: Type Ia: Fas; Type Ib: Fas ligand; Type Im:
somatic mutation of Fas; Type II: Casp-10; Type III: unknown genetic defect;
Type IV: N-Ras (neuroblastoma Ras, a molecule involved in the regulation of
cytokine-withdrawal apoptosis); and CEDS (Caspase-8 deficiency state):
Casp8 homozygous gene defect. Bim stands for BCL-2-interacting mediator
of cell death.
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role in the induction of the
NF-kB transcription factor
during lymphocyte activa-
tion as well as in apoptosis
mediated by the Fas DISC
(Su et al., 2005). Type III
designates ALPS of un-
known molecular etiology,
which is a potentially ex-
citing source for new dis-
coveries. Umberto Dianzani
(University of Eastern Pied-
mont, Italy) discussed ALPS
variants with severe auto-
immunity, lymphoprolifera-
tion, and defects in Fas ap-
optosis, but normal DNTs.
Gene defects in osteopon-
tin and perforin may underly
these variant syndromes
(Clementi et al., 2006). Fi-
nally, ALPS type IV patients
harbor somatic activating
mutations in oncogenic
Ras genes (for example,
a G13D mutation in N-Ras)
that also engender a pro-
pensity to hematopoietic
malignancies (Oliveira et
al., 2007). Joao Bosco Oli-
veira (NIH, USA) described
how activated Ras mark-
edly decreases Bim protein
expression leading to im-
paired lymphokine with-drawal and TCR-induced apoptosis.
Interestingly, a subpopulation of patients
with a disease resembling juvenile myelo-
monocytic leukemia (JMML), which is
typically fatal in infancy, have a markedly
milder condition with features of ALPS
Type IV. Lesson #3: as more genes are
identified in thepathogenesis of adisease,
the clinical heterogeneity of the disease
broadens to reflect the physiological
effects of the involved genes.
Lesson 4
Elaine Jaffe (NIH, USA) described the
characteristic histopathology of ALPS
that affects multiple immune cell com-
partments including lymphocytes, macro-
phages (histiocytes), and dendritic cells
(DCs) (Lim et al., 1998). Increased DNT
cells in the lymph node cause follicular
hyperplasia and prominent expansion of
the paracortex, which can be mistaken
for T cell lymphoma. In fact, caution292 Immunity 32, March 26, 2010 ª2010 Elseshould attend a diagnosis of T cell lym-
phoma in ALPS because DNT expansions
typically remain polyclonal and nonmalig-
nant. The DNT cells are CD57+, possibly
suggesting cell senescence, and usually
express high amounts of Fas and Fas
ligand despite the apoptosis defect in
ALPS. S-100+ histiocytes can also be
increased amidst the DNT cells. The
S100+ histiocytes show evidence of em-
peripolesis (penetration of lymphocytes
and plasma cells within the histiocytes).
These features are characteristic of
Rosai-Dorfman syndrome, a rare pedi-
atric disease characterized by cervical
lymphadenopathy and autoimmunity.
This condition, also referred to as sinus
histiocytosis with massive lymphadenop-
athy, may represent a forme fruste of
ALPS. Histiocytes and DCs in ALPS
apparently share the same apoptotic
defects as lymphocytes, and a single
case of histiocytic sarcoma has beenvier Inc.encountered. Lesson #4: al-
though autoimmunity is gener-
ally thought to arise from
lymphocyte disturbances, ab-
normalities of dendritic cell or
macrophage homeostasis and/
or function can also play an
important role.
Lesson 5
Stefania Pittaluga (NIH, USA)
reviewed the 50-fold and 14-
fold increased incidence of
Hodgkin and non-Hodgkin lym-
phoma, respectively, in ALPS
(Straus et al., 2001). Defective
T cell surveillance, Epstein
Barr virus (EBV) infection, and
defective B cell apoptosis may
all predispose to lymphoma.
Also, high levels of IL-10 due
to a skewing of peripheral T
cells to a Th2 cell phenotype
or from expression of the
BCRF1 gene in EBV (viral
IL-10) may similarly contribute.
Studies of sporadic lymphomas
have also uncovered Fas muta-
tions (Takahashi et al., 2006).
Louis Staudt (NIH, USA)
described how mRNA expres-
sion microarrays can delineate
molecular subtypes of lym-
phoma that have distinct treat-
ment susceptibilities and prog-
noses. Nevertheless, exceptfor the general notion that a failure of
apoptosis in ALPS can lead to B cell
expansions, there is a limited under-
standing of the propensity to lymphomas.
Lesson #5: the Fas pathway plays a
general role in preventing B cell
lymphomas.
Lesson 6
The defining characteristics of the
disease and the variability among individ-
uals and subtypes of ALPS were dis-
cussed. Importantly, individuals in the
same pedigree who harbor an identical
Fas gene mutation can manifest a wide
range of disease symptoms. This variable
penetrance has not been explained
molecularly, but might stem from as-yet-
ill-defined ‘‘background’’ genetic differ-
ences or environmental factors. It is
notable that backcrossing the lpr or gld
mutations into different inbred strains of
mice also yields heterogeneous disease
Immunity
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gene defects in genetically diverse indi-
viduals is emerging as a recurrent theme
in human diseases, in contradistinction
to mice or other inbred experimental
organisms. The marked phenotypic varia-
tion in humans raised questions about
what clinical findings should define
ALPS. Theclassic triad required for a diag-
nosis of ALPS includes chronic lymph-
adenopathy and splenomegaly, a func-
tional defect in lymphocyte apoptosis,
and elevation of DNT cells. It was also
noteworthy that despite the many cell
types and tissues in which Fas apoptosis
has been studied, the clinical abnormali-
ties in ALPS patients are largely confined
to the immune system. Koneti Rao (NIH,
USA) summarized the clinical spectrum
of ALPS observed at NIH Clinical Center
over the last 15 years in more than 250
patients. He showed that disseminated
lymphoproliferation can be readily visual-
ized by CT scan. When hematologists
see young patients with cytopenias and
enlarged lymph nodes and splenomegaly,
they must be circumspect in raising the
issue of possible cancer until ALPS or
related nonmalignant causes have been
excluded. ALPS patients generally exhibit
hypergammaglobulinemia, monocytosis,
and eosinophilia, and bone marrow biop-
sies often reveal the characteristic histo-
pathology as well as the pathognomonic
DNT cells. Lesson #6: Fas pathway
defects chiefly cause immunological ab-
normalities and humans, unlike inbred
mouse strains, exhibit substantial pleiot-
ropy and variable penetrance associated
with gene defects, presumably because
of background genes or environmental
differences that exist between individuals
even within the same family.
Lesson 7
Most problematic for ALPS diagnosis is
the functional apoptosis assays for pe-
ripheral blood lymphocytes. The partici-
pants discussed two challenges. First,
what should the defining apoptosis defect
be? Thus far, apoptosis abnormalities in
phytohemagglutinnin A (PHA) and IL-2
activated T cells from ALPS patients
have been identified in direct Fas-trig-
gered death (Type Ia and II), TCR-induced
death (called restimulation-induced cell
death [RICD]) (Type Ia, Ib and II), and
lymphokine withdrawal death (Type IV).
Hence, the relevant apoptosis ‘‘defect’’for ALPS actually differs according to the
precise molecular defect. Thus, a Fas
apoptosis defect is too narrow to define
all cases of ALPS. Second, how can
assay standardization and efficiency be
achieved across medical centers that
currently have widely varying procedures
and results? This variability is less in
prototypical Type Ia patients and perhaps
greatest in type III patients, suggesting
that it also relates to the nature of the
gene defect involved. Richard Siegel
(NIH, USA) called attention to the varia-
tions in PHA+IL-2-stimulated T cell prepa-
rations stemming from culture incubation
times (which can be days to weeks).
Consensus emerged that there was a
need for a rapid assay on fresh cells. Sie-
gel related that particular CD4+ T cell
subsets are selectively susceptible to
Fas killing in normal individuals. Thus, a
tailored approach to specific subsets
might yield a more effective assay.
Certain medical centers have established
well-controlled assays, which generated
optimism that consensus assays could
be developed as standards for the field.
Lesson #7: human clinical testing for
uncommon diseases can lead to great
variability between medical centers, and
such variability can only be overcome by
rigorous cross-comparison of testing
protocols and standards.
Lesson 8
As with many genetic disorders, genomic
DNA sequencing without functional as-
sessment is increasingly being used
for diagnosis. Most single-nucleotide
changes in ALPS can be detected by
commercial testing services. This can be
useful in local centers especially when
the mutation has been previously con-
firmed to be functionally deleterious.
However, demonstrating a functional
apoptosis abnormality is important for a
rigorous diagnosis of ALPS. Tabulating
known ALPS-associated mutations
around the world in a widely accessible
format can now be achieved through the
Leiden Online Variant Database (LOVD)
described by Lisa Forman (National
Library of Medicine, USA). This is a new
open-source Web site capable of col-
lating mutations in any genetic disease.
The National Center for Biotechnology
Information at NIH will establish an ALPS
site linking LOVD Web pages for each of
the genes encoding Fas, FasL, Casp-10,Immunity 3etc., which will be managed by Joao
Bosco Oliveira and Julie Niemela (NIH,
USA). Locus-specific internet databases
linked by disease portals will probably
become a foundation for genetic disease
research and clinical management.
Lesson #8: cataloging mutations associ-
ated with rare diseases has become
more effective with open-access, Web-
based tools such as the Leiden Online
Variant Database.
Lesson 9
Jack Bleesing (University of Cincinnati,
USA) described a flow cytometry panel
used at Cincinnati Children’s Hospital
Medical Center as a diagnostic screen
for ALPS. It defines a quantitative immu-
nophenotype including the number of
DNT cells, the ratio of CD25+CD3+ to
HLADR+CD3+ cells, increased B220+
T cells, and decreased CD27+ memory
B cells. This panel facilitates ALPS patient
classification. Nevertheless, pleiotropy is
also observed in various ALPS markers
in specific patients and the normal ranges
for the markers vary with the age of the
patient. It was discussed that the ab-
normal lymphocyte populations, as well
as disease severity, decline as patients
age past puberty and the thymus invo-
lutes. Other biomarkers that are dramati-
cally increased in ALPS include soluble
Fas ligand, circulating IL-10, and, surpris-
ingly, vitamin B-12, whose biological
provenance is unknown. Combinations
of these markers can be highly diagnostic
of ALPS in lieu of Fas sequencing and
Joao Bosco Oliveira and Tom Fleisher
have been working on a diagnostic algo-
rithm for ALPS utilizing flow cytometry
and serological markers. A new con-
sensus ALPS classification and revised
diagnostic criteria will expedite collabora-
tions and standardization between dif-
ferent centers.
ALPS diagnosis has been beneficial to
families with this disorder. Although the
genetic lesion and biochemical pathway
cannot be directly corrected, the medical
importance of knowing the molecular
etiology of ALPS should not be underesti-
mated. In many cases, knowledge of the
gene defect preventsmisdiagnosis, espe-
cially confusion with lymphoid malignan-
cies, and the administration of unneces-
sary and potentially toxic treatments.
The natural history of the disease is vari-
able and many patients can live with no2, March 26, 2010 ª2010 Elsevier Inc. 293
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ties. Most patients receive immunomodu-
latory agents such as corticosteroids,
rituximab, mycophenolate mofetil (MMF,
Cellcept), intravenous immunoglobulin,
and, most recently, rapamycin (sirolimus).
It is a telling insight into the current state of
immune therapeutics that corticosteroids,
despite substantial metabolic and immu-
nological side effects, remain the initial
and perhaps most reliable treatment for
ALPS. Other aspects of clinical manage-
ment include CT scans (every 2 years),
the application of spleen guards (because
children are prone to traumatic rupture of
their enlarged spleens), and antibiotic
prophylaxis postsplenectomy for pneu-
mococcal sepsis. Avoidance of splenec-
tomy is increasingly successful by treat-
ment with mycophenolate mofetil and
rapamycin, which remains the corner
stone of managing these patients today.
David Teachey (University of Pennsylva-
nia, USA) discussed the therapeutic effec-
tiveness of rapamycin and other targeted
therapies in ALPS. His group first showed
that rapamycin, anmTOR kinase inhibitor,
was highly effective in lprcg mice, which
have disease manifestations similar to
ALPS due to Fas mutations. Studies in
the clinic revealed that rapamycin in
some cases could dramatically resolve
the disease manifestations of ALPS with
renormalization of DNTs and resolution
of lymphadenopathy, splenomegaly, and
autoimmunity (Teachey et al., 2006). This
agent probably resolves disease symp-
toms with its ability to efficiently eliminate
DNT cells; such a finding is not observed
with other agents. However, termination
of the therapy resulted in the return
of disease manifestations. There were
also significant concerns regarding side
effects of rapamycin especially in chil-
dren. Some patients do not respond to ra-
pamycin and these might be managed by
drug combinations, for example, mTOR
inhibitors, mycophenolate mofetil, and
methotrexate. Teachey and colleagues
also have targeted notch signaling in
ALPS by using gamma-secretase inhibi-
tors. These agents had promising effects
on disease manifestations in preclinical
studies (Teachey et al., 2008); however,
they are not yet currently available for
clinical testing. Thus, the future of ALPS
therapy may portend agents that are
more disease-specific and potentially
less toxic than currently available agents.294 Immunity 32, March 26, 2010 ª2010 ElseLesson #9: for autoimmune complications
arising from abnormal lymphocyte ho-
meostasis, corticosteroids remain the
initial drug of choice, although newer
steroid-sparing agents are being devel-
oped and tested.
Lesson 10
Further insights into what lies ahead in
ALPS research were provided by the final
talks. From the clinical side, Nichola
Cooper (Institute of Child Health, UK)
reported that increased DNT cells are
found in some immune thrombocyto-
penic purpura (ITP) patients, suggesting
a syndrome overlap with Fas function
and ALPS. Stefan Muljo (NIH, USA)
described microRNA research indicating
that genetic diseases such as ALPS
deserve further analysis of microRNAs
as potentially causative agents, bio-
markers, risk factors, or even determi-
nants of disease penetrance. Lorraine
O’Reilly (Walter and Eliza Hall Institute,
Australia) described studies in the labora-
tory of Andreas Strasser in mice geneti-
cally engineered to selectively express
either the membrane-bound or the
soluble form of Fas ligand (O’ Reilly
et al., 2009). She has determined that
membrane-bound Fas ligand is required
for T cell-receptor-induced death and
the lack of this form of Fas ligand can
lead to lymphoproliferation, autoimmu-
nity, glomerulonephritis, dermatitis, and
an increased incidence of histiocytic
sarcoma. Hao Wu (Cornell University,
USA) described a new structure of Fas:
Fas-associated death domain (FADD)
protein death domain (DD) association
that has an interesting symmetry of inter-
locking DDs that reveals how Fas DD
mutations in ALPS actually map to inter-
faces and disrupt function. The oligomeric
nature of the Fas and FADD DD complex
may facilitate cooperativity in signaling.
The structure provided the participants
with a visual representation of how
specific mutations could generate the
dominant-interference that constitutes
the genetic basis of ALPS. Lesson #10:
structural and biochemical examinations
of the signaling protein complex are key
to illustrating how gene mutations cause
disease.
Concluding Remarks
In summary, the conference stimulated
discussion that coalesced around thesevier Inc.lessons that are germane to ALPS and
other human genetic disorders. There is
important overlap in the features of
ALPS and common variable immunodefi-
ciency (CVID), familial hemophagocytic
lymphohistiocytosis (FHLH), and X-linked
lymphoproliferative disease (XLP), espe-
cially because XLP involves defective
apoptosis (Snow et al., 2009). Perhaps
the final lesson for the participants was
that the intensive molecular, cellular, clin-
ical, and therapeutic investigation of rare
genetic diseases such as ALPS provides
a wealth of insights into normal immune
system functions.ACKNOWLEDGMENTS
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